1992
DOI: 10.1016/0264-410x(92)90022-c
|View full text |Cite
|
Sign up to set email alerts
|

Current progress towards vaccines for arenavirus-caused diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
10
0
2

Year Published

1993
1993
2013
2013

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(12 citation statements)
references
References 44 publications
0
10
0
2
Order By: Relevance
“…Low-titer neutralizing antibodies, if formed, typically appear several weeks to months after the resolution of infection (9,14,20). Furthermore, the treatment of LF patients with immune plasma did not protect against disease (14,19).…”
mentioning
confidence: 98%
See 2 more Smart Citations
“…Low-titer neutralizing antibodies, if formed, typically appear several weeks to months after the resolution of infection (9,14,20). Furthermore, the treatment of LF patients with immune plasma did not protect against disease (14,19).…”
mentioning
confidence: 98%
“…One of the hallmarks of LASV infection is the absence of detectable neutralizing antibodies during acute infection (9,14). Low-titer neutralizing antibodies, if formed, typically appear several weeks to months after the resolution of infection (9,14,20).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, vaccine strategies aimed at generating a CD8 ϩ T cell-mediated response confer protection against virus challenge in murine (13,14,56), guinea pig (5, 69), and NHP (36) models of LCMV and LASV infection. In humans, cell-mediated immunity also seems to be critical for protection against LASV infection, as neutralizing antibodies appear several weeks or months after viral clearance (28,37), and treatment of infected patients with immune plasma does not protect against disease (65).…”
Section: Cd8mentioning
confidence: 99%
“…This is particularly true for the pathogenic Old World arenaviruses LCMV and LASV, as high-quality antiviral nAbs typically do not form following infection with these viruses; low-titer nAbs, if formed, usually appear weeks to months following clearance of the primary infection (11,14,18,21,34). In the case of LCMV, it was recently shown that the GPC itself, not the viral backbone, is responsible for this poor nAb response (40).…”
mentioning
confidence: 99%